SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen), announced today that patient enrollment has started in a new Phase 2 clinical study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis (IPF).
IPF is a debilitating and life-threatening lung disease characterized by a progressive scarring of the lungs that diminishes functional lung volume and hinders oxygen uptake. The cause of IPF is not known, and approximately two-thirds of IPF patients die within five years after diagnosis.
Help employers find you! Check out all the jobs and post your resume.
